R&D News | pharmaphorum

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

News

Biogen shows its IgAN hand with felzartamab data

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t

News

kidney disease computer graphic scan image

Novartis eyes year-end filing in US for Fabhalta in C3G

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl

News

GSK plans $800m US manufacturing investment

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.

News

MSD buys Modifi for $1.3bn to boost oncology pipeline

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.

Novartis pays $150m upfront for Monte Rosa degrader drug

MSD, Moderna start phase 3 adjuvant lung cancer trial

Biogen shows its IgAN hand with felzartamab data

Novartis eyes year-end filing in US for Fabhalta in C3G

GSK plans $800m US manufacturing investment

MSD buys Modifi for $1.3bn to boost oncology pipeline

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks